<SEC-DOCUMENT>0000912282-12-000119.txt : 20120208
<SEC-HEADER>0000912282-12-000119.hdr.sgml : 20120208
<ACCEPTANCE-DATETIME>20120208133916
ACCESSION NUMBER:		0000912282-12-000119
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120208
FILED AS OF DATE:		20120208
DATE AS OF CHANGE:		20120208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		12580956

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>oncolytics6k_02082012.htm
<TEXT>
<html>
<head>
    <title>oncolytics6k_02082012.htm</title>
    <!--Licensed to: Dorsey & Whitney-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of February 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="70%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NEWS RELEASE DATED&#160;&#160;FEBRUARY 8, 2012 &#160;-&#160;<font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">ONCOLYTICS BIOTECH<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#174;</font> INC. CLOSES BOUGHT DEAL FINANCING FOR TOTAL GROSS PROCEEDS OF CDN</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">$21.3 MILLION</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;February 8, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="TEXT-DECORATION: underline">/s/&#160;&#160;Doug Ball<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>PRESS RELEASE DATED FEBRUARY 8, 2012
<TEXT>
<html>
<head>
    <title>ex99_1.htm</title>
    <!--Licensed to: Dorsey & Whitney-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">EXHIBIT 99.1</font></div>

<div><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<img src="oncolytics_logo.jpg" alt=""></font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">&#174;</font> Inc. Closes Bought Deal Financing for Total Gross</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Proceeds of Cdn$21.3 Million</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB &#8211; February 8, 2012 &#8211; </font>Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221; or the &#8220;Company&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced that it has closed its previously announced Cdn$18.5 million financing in which it entered into a revised agreement with a syndicate of underwriters (the &#8220;Underwriters&#8221;), pursuant to which they purchased, on a bought deal basis, 4,405,000 common shares (the &#8220;Shares&#8221;) of the Company at a price of Cdn$4.20 per Share for gross proceeds to the Company of approximately Cdn$18,501,000 (the &#8220;Offering&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Offering, the Underwriters have exercised in full an option (the &#8220;Over-Allotment Option&#8221;) to purchase an additional 660,750 Shares sold under the Offering at a price of Cdn$4.20 per share, on the same terms and conditions as the Offering. With the Over-Allotment Option exercised in full, the aggregate gross proceeds of the Offering to Oncolytics are approximately Cdn$21,276,150.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Shares were offered in Canada by way of a shelf prospectus supplement to a short-form base shelf prospectus dated June 10, 2010, that has been filed in the provinces of British Columbia, Alberta, Manitoba and Ontario pursuant to National Instrument 44-101 and National Instrument 44-102.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics intends to use the net proceeds from the Offering to fund its ongoing Phase III combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers, its other clinical development and research and development activities, including manufacturing, and for general corporate and working capital purposes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The securities issued by Oncolytics have not been and will not be registered under the U.S. Securities Act or the securities laws of any state of the United States, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable securities laws of any state of the United States or pursuant to an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy in the United States nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company&#8217;s expectations related to the application of proceeds and the ability to fully fund the program as anticipated; the Company&#8217;s belief as to the potential of REOLYSIN as a cancer therapeutic; the Company&#8217;s expectations as to the success of its research and development programs, including its manufacturing program in 2012 and beyond, the Company&#8217;s planned operations, the value of the additional patents and intellectual property; the Company&#8217;s expectations related to the applications of the patented technology; the Company&#8217;s expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company&#8217;s business and technologies involve known and unknown risks and uncertainties, which could cause the Company&#8217;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company&#8217;s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oncolytics Biotech</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.670.7377</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.283.0858</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">dball@oncolytics.ca</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td align="left" valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Investor Relations Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Erika Moran</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11 Stone St, 3rd Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10004</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">emoran@investorrelationsgroup.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>oncolytics_logo.jpg
<TEXT>
begin 644 oncolytics_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`&`!
M0`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^****'H`5"\P!*`,6XP!C)!.,CG.>#CCMGI7,^.?&WA?X<^$=
M?\=>--=L?#?A/PMIEUK6O:WJ$FRVL=.LX7FFDVJKRW$T@416MI;)+=WER\-K
M:0S7$T<3?SP^)/VI?VM/^"GWQ0OOA'^R2^O_``3^`.D2>=XN^(]V9],U22UB
M@NT+>+=>TI)9;+^WH[J%=)^'>BW+7]U/"]WJMZMI97%SI_F8_-*&!=*BX5*^
M,Q/.L+@Z/*ZU=PCS2EJ^6G2CM.K/W8O:,W:+TITI3N[J,(VYIRTC&[LEYM]$
MM_(_7/XT_P#!0W]D/X"W]UHGCSXOZ'/XDLHO-NO#/A%+GQCKT*^<8/+FM/#\
M=XD=P)4E5[66=+F,PRB6)"A%?.__``^?_83_`.AK^(O_`(:KQC_\A5R/P5_X
M(L_LK^`+71K[XFOXI^,OBRUGTW4M4GUC4;GP]X/O-9BEM[J^">&=%EA>^T>^
MNH9A<6/B/4M=EO+:YFBU&XN3,&7[*_X=]?L1_P#1KGP8_P#")TK_`.-5YR_U
MGKMU8K*<%&5G&C66)Q%5*R?[R<53@I+9J*M?T1?^S*R?MIOJURQ5[KX=9-KU
MMVU3N-^#'[?'[)GQ[O;71/AW\8_#EQXFO;5;R#PIX@DF\+>)&A,ME;E$T_7H
MK'S;A+F^M[4VEO+-<M<%XDB8HV/L!95+;.=P'.<`^G0G/KGCC!K\8_C_`/\`
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M8Y_P"BBBF`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!2,<#IG)Q2UP7Q0\8V_P\^'?CWQ[>N8['P3X
M)\4^++I]H;;%X>T:\U5V`*N"0MJ<*4<'H4(R#,Y1A"4Y.T8)R;TVBKO?3H'5
M+JVDK:ZMI+\6?A+_`,%`_B/XN_;5_:B\"?\`!/'X,ZJ?^$/T;7]/UOXZ:_8Z
M7(9=$UK1)Y;W4EGN[R:.RNM)\%:#=6NH"WCCV7GC6ZTVT#S&PP?VT^!WP.^'
M?[/OP^T#X<_#+0K/0]"TBPL8;F>&V@BU'Q%J=KI]K8W/B/7[B&.)M0US51:I
M<ZA=R`!YVD:-(D(2OQZ_X(E?#[6O$VD_'O\`:O\`B!!>ZKXV^+7C2?0+'Q?J
M,8CFUG3[.X.M>+[RQ$<*0"VOO%=U%I]T('6"VG\-)I]M:VD%HHF_>?`XQQMX
M';MBOG<CI/$J><UX)XG'RO2<E>6'P*:5"A3DUHIRC[6;5G-RUT1O6?+:C%OE
M@ES+I*;2<FTGKKHD_AM8.?4?EV_/]?TI:**^D,`.>V/Q&?ZBOGG]I+]FOX:_
MM/?#?6OA]\1]'L+M;K3]4A\.>(Y;"VO-:\%ZOJ-F;5->\/S7!3[/>0$1NT!E
M6WNDB2&Z#QYKZ&IKC<I&`0<<'GOZ5C6I4JU.5&K3C4I5/<G&235I.U[-=+WO
MNGJAI\LE)-QE?XEHUMU7Y=5H?SS_`/!)?]HCQK\+/B5XM_8!^-LMIH=[X*O/
M%`^&5IJ]MJ=MK$FN:7K%S=^(O"UE>7`6SN=*O+%KGQ1X6<V]E!>:=',VEO<)
M<VRR_P!#"MN[8Q7\^?\`P6#^'>F?!GXI_LV?MI^"DN_#WC'3/B7H/A[QIJM@
M88+/4_[`6'7=`U"[=;9Y/[9_L/3O$6BS7$K7'VG1H(8TM@UAYDO[\:'J=OK.
ME:=J]I*DUIJUA9:I:R1.)(7MK^UANH&AD4!9(S'*"L@^^#NX'`\3(Y5<//'9
M57FYRR^I3E0J/_EY@JT'[!:W_AJ#A)W;NK-Z&M6TN6JE936N_P`:2YMWIJ[I
M::>1K44@8'.#G'!X/7T_Q].]-,B#JZ_F.W'\^/K7T-U>U];VMUO:]O6VMNVI
MB/HI-R]<C'7/;KCKTX(Y&<BEHNEJW9;7\]-/Q7WH+I[._7Y/9A13=ZYQD$\\
M#D\=>!D\=Q2A@<X/3K['`.#Z'!!P><$'H11==]MP%HI`RD9!!'KGU&?Y4F],
M@;ER>@!!S[<=_;OVH"Z[CJ*3/U_(_P"''XTFY<[=PSUQGGKC^8(^HHNENP'4
M44F1D#/)R0.Y`QDCUQD9^M`"T449_P`X-`!130RGHP].M`93G!S@X.,D9],C
M(S2NG:S6JNM5JNZ[KS0#J*:'4G`()Z\<_J.*=3`**3/U_(C^8H9E4%F(`'4]
MJ`%HI"0.IQ]?Q_P-(74=6`^I]?\`]=)M)7;25KW;25N_H`ZBFAE.2#G'!QD]
M?I_G'/2E)`Y)`'J3@?F>.U#:6[2]78!:*3<,;LC;@G/;`Z_E4;SPQQ/.\L:0
MQH\DDSNJQ1QQJ6D>21B$1$4%F9B%5022`*=UW_K?\M0):*8LB,BR*ZLCJ&1P
M0592,AE(X96!!5AD,"""013@0P#*001D$="*`%HHHH`*^$?^"FVN:SX<_81_
M:0U70-3O-(U$^"]/THWMC((KC^SM>\6>'M"UJRWE7'V?5-&U*_TR\3;F2TNY
MXP5+[A]W5\A?M]>!%^)7[&O[1OA(W=[9-)\+]>\10RZ?9KJ%Y-=>"?(\:VFG
MPVC,GF#5+KP_#IDK(6FBBNWFMXY9HDC;CS!2>`QJA=R>$Q"C;1\WL9\K[[VV
MN_)ETVE4IM[*<&_123?X'!_\$P-!T;0?V$OV<QHVFVNFC6O!!\1:JMHAC6^U
MW6-5O[G5=5N`2Q>\U"X/G7,F0&D)*JHP!]\U^8?_``2&^*5A\2/V(_AKI4!L
M(M4^%<FK?#/6K"SN+FXFMI-%O&OM)NM0\^"%8+S6-#U/3]7:VMVN(((;R%5G
M+;HX_P!/*QR>5.>4Y;*DTZ?U'"J-MERT(1:>VJDFGYH*J:JU4_\`GY+[NGR"
MBBBO2("BBB@#\O?^"Q%I:W'[!OQ2FGMK>>6T\0_#&:TEF@AFEM)9/B%X>M7F
MLY)$9[2=[:XN+9YX&25[:XGMV8P3RQM]-?L/-)+^Q[^S#/++)-))\"OAH7EE
M=Y)'9O"VFN2[R,SL03@%F)`XR:^*_P#@M=\0])\)_L:ZCX/NX;BZUCXH>.?!
M^B:'#;21JUL?#6J0^,]2U"XB=6>XM4M]#BTU8K<_:/[0U6P<*UO'<%?OW]EC
MP;JGPZ_9N^!'@/6IK6?5O"'PD\!:%J<MDSO:27NG^&]/AG:V>0)(T(=-J,R`
MLO)'2O`I-3XAS!1=^3*\%"I9.T93Q&)DDWHE+EDI>DD]4;O_`':GH]:M5_)*
M$?6S=[=+W/QE_P""O>D?$/QK^T[^RE\*?A]X\\1^"M4^(WA_6_#MA/IGB?Q#
MH&D'6-1\0"'3Y]8CT&]MB\#3K!:RWI@N;BUAD:1(IE0PO]1_\$[_`-OR]^.%
MUJW[.GQ[CMO"G[3'PWFO]"N;2X4Z:OQ`MO#1N++59;6UO)8YE\::0=/NKWQ+
MI<,"Q2V136+%#$+^.S\7_P""BS)_P\4_X)WA@,#7+?'&>&\80AOYX/<\]:]3
M_P""CO["WB3QM<P_M:?LO2W_`(._:7^&:G7+N/PHL=IJ'Q#TW2+>9Q/8PPPF
M*[^(6G0I%!IDNH+-;^(-*BDT"_BG;[`J^2I8ZEF.<9AA:E;$PPF*I4\3E^K5
M?#1H0E*>'BDY+$T6I2IJG95HIT]9-(OW'3HQFHKFBVI]5)NR4M5>.RT>GR/,
MM0O-<TS_`(+?:9HD'BGQ:WA_6_AC%KEQX9G\1ZQ)X9@O4^'?V$M:>'OMHTB!
M)$TZ&Y8BR\PWDMS=$^;,6K]QM2U&TTJRO=4OIA;:?IUG<ZA?W+!REO9V4#W-
MS.RHK.RPP1O(556=@I"JQ(!_EP_8L_:&\1?M.?\`!3;X/?$[QGI,6C>-8_A)
MKG@_QA;PPSVL5SKWA3POJ.F3ZI]BN8H)M.N=4A%O>7^F-#&FG:C-=6<0\J&.
MOZ;O'GAA/&?@OQ?X.EE:"'Q9X5\1>&)KA&*-;Q>(-'O-)><,H9U,*W9D!568
M;=RJQ`!]#(<0\12S.M2E*K"6:8R5#VC;E&'LJ+A3DI7Y'&HK..Z6C>UHK149
M4XVBK4X*7+:S:O=^Z_/R\E8_$+P3\1?C7_P5E^(7Q2\.^%?B'XD^`'[&_P`.
M-;T_3+M_!`MM+^*_Q&U8*=2TFTU;7!?7-UH(>:VM]=N[>QBETN/2GT_3XWGU
M<7=W%],VO_!*/X<Z%>Q:UX+_`&C/VKO"7BK3YXKS1O$MK\7]5UB[TN_MW017
M@L->CU'1]1DCMQ):JFJ:?=P^7+DH6BB*_"/[`'QK\/?\$Z/'WQ0_9#_:HT^;
MX;W&N^/SJ7A+XMW&E72>`]>%OH.G6^GVMUXFEMTN[Z#5;4V\VE:HL5S8:7+<
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M'Q;TZRM=8\8WMMX=CL)M7L/!LMNS+X62VNG_`.$9.H3727-S=ZS(+I+>*#[%
M<_L]X.\8^%?B!X8T/QKX'\0:5XJ\)>)-.@U;0M?T6]AOM,U.PNHED@N;:YA9
MD8,K!9(VVS02J\,\<<T<D:_SO>/M'UK_`()[?\%-[C]I7XA69M_V>OC]K'CP
M7WC#P]!J6H6OART\8'2[O6/^$IB-I/)IUQ8>+!I6KSQ*^+^P-[+I3%K9;%^S
M.ZM2G1P#A.<<!4QM&GCZT*O*Z>%G.$4W5C)VBY\L)<LE>$G&]FQ44N:=_C4&
MX*4;^]>.\6MTKV5M'MM=?<L7_!(_X+);113?'']JV206\<$LI^./BF%YG,8B
MDE,<5R(4>=LRE(@(U+[8U5<`?./@3]IGXZ_L-?M>^!?V,/CE\0K#XQ?!7QA>
M:1%X#^*GC0QZ9XZ\,>'?$:W>F>$K#5M8-['8W<.A:G9V.D:O)K"E[A9&GTHA
MIX88_P!A+3]HG]G_`%'3[*_L?CC\(Y[:[MK:\M9#\1O"$)DM[F-)87:.?5XY
MXB\3JS)+%%+&25=4=2H_!?XVZ1IG_!03_@I_\-=,^%-IJ/C+X3?`M/#>G_$W
MXBZ'''8^&;8>"/$DWB37$T?Q9#:36^J2KKATW0])S)=_VG>_:TTM%TJWGU!>
M3,8T,']4J96U'%U<QP])4L-4<Y5L-.?[Y5*<:E5.E&FHRE-QO'O&XZ;<W+VN
ML.233:4;2MI:R5G?;5IZKH?TEW3EK*\(#*5MI_4'/DL>",$$'CLP([<$_BG_
M`,$7?$/B+Q!H7[54GB#Q%XA\0M9?&PVUDWB#7-5UQ[&W,6K$6UB^IW=T;.U`
M5?\`1[<QQ`@?+P,?M3<AA8WN[.3;W)&>N3')G`'0$].2<<'.`3^`G_!&[XH?
M#7P1IW[5VE>-/B#X+\(:E<?&B*_MK+Q3XFT?P[/=V4HUV$75HNL7MFMY%YUO
M-%*ULTOD.H681^9%YG9F%7V>;Y$YU%3A*.9*7/54(N3H48QO!R49W<FTFGRV
M=GKK,+.C6]V\N:GK9NRO+KLKO3S/Z"0,#&<^]?F9_P`%&?V-?%?[1?@Q?'/P
M6\8>+O!OQV\"::TVAVN@^,O$.@:/\0M$T^2?43X.U6QL=9T_28M5:\=Y?#NM
MW<:K;W<\UAJ+OIUXTEI]SZ-\:?@]XBU.TT70/BQ\,]<UC4)##8Z1HWCOPOJ>
MJ7LP5G\JSL++59[JZD"*S%((G;:K-C`)'I+)'(I)57QR,@'Y@"`1GC(!('ID
MCN:]2M"CC\-.C*7-3JKE=2E5:E!IIQG"=-WC)2U6O*[<LKIM&492IR4DE>+3
MM)73\I)IW3ZKJ?CQ^QO_`,%2O`'C;X<^+_#_`.TYJL'PM^-/P1T._E\?PZZL
M&F0>+X?#DEU9ZIJ'ARP:874WBNUN+18?$7A>*W6XBOKJ&?3?M-I)/]A\=^#5
MG\7/^"H/Q]T[]H?Q9<>-OA-^R#\)=3^Q_#'P1I/B'5_#^J?$[6;"ZM+F\NM?
MO-#N]/&J6,FI645UJLK":UL;40^&+)I9SJ]Z_CW_``5[_9\^%6F_M*?LH^,;
M'PXNFZS^T'\18_"7Q8^P3O;6?BBSTSQ+\/-%AU22UC`6T\0S:/XFO=.O-6MY
M$-Y!!I[3Q-<VS3S_`-$O@OP7X4^'GAC1/!7@?P]I7A7PGX;L5T[0]`T2SAL-
M,T^T1W=E@MH%1`\TSRW-U,P:>[NYY[NYDEN9Y97^>P5/,,;BJF`Q^(C*AD]>
MG[9T7*G4Q\ZM*&)P<Z[CRNFJ,'%U:<6J=6<N62E".O1-TX152FFI5E)VE9J"
MO:?*N[DG9M6MM9GD'[1?[.?AG]I3P58>!O%GBGQ_X3TZQU^U\0IJ7PZ\5:CX
M0UR:[M()X$MI]2TN6.9].=+AVELSE)'2-SR@S_/;_P`%0/V5M)_8V^'_`,-O
M%?PK^,/[0%WJ7B[Q5K&B:FGBGXO^,M5MQ::?HIU"!K=(]3M_+E,YVLS;LQY'
M&!7]3&%49QT(/?\`#^=?@9_P7T`'P7^!@S_S4+Q/W`X_X1;MD]\]<G)P*Z>(
ML-1_LW&XEPOB(4J;C64ZD9)J<(I\M.<+::6BK-7>KNB,/)JI3A?W?>NG&+5K
M=WZ=?7H?1'A?_@E1\'K[2?#&NW7QJ_:BEGN;'0=:N;=_C=XM:TN+EX;/4IXI
M8S=$FVN9]RSQ!P7A=HMP4YK]77MX[?3?LT`\J*WLVA@52Q\N.*W9(E5G9G/E
MJJ@%F9N`2Q;YJQ?!"J?!WA,G!SX8\/\`U_Y!-IU_^O6]=,!;7.>!Y$Y!S@!1
M$X'T/K[UZ]##4L/3;I04'*$9R<5+F;A#1^].>J;VLK]>ADY.3C=N6J6J7E_3
M]+[MG\[G_!##Q5XM\3>-?VIU\3>+?%?B=;*R^'36<?B3Q+KFOQ63S:W\01.U
MA%J]_>I9&80PK*;81F1(85?<(D"_K1^W#^U5I7['_P`"M8^*=QI'_"1^(KJ]
MM_"W@;P^TJ16FH^+]7M[Q]-FUEA<VUTOAW3EMI;K69=/\Z]$*1P1+";D7,'X
M]?\`!!8_\5O^U>>"38_#4C!SD#7?B*.OOCOUZ]*_2/\`X*F?LO\`C;]J3]F:
M\\/?#<)=>-/`OB"+QYIF@,7$WBFUTS2M3MM2\/Z85VK_`&[>V]RKZ,D\D=O/
M>1"U=TDN(I$^=RROBUPRZ^%<ZV,C#'NC*47*<IK$56K4Y_$J<4W"GM)Q4$M4
MCHJ*'UA)_"W3;:ZIQ5]=EKVTUOT2/EGX$_LO_'+]OCP+X&_:+_:P_:1\<Z9I
M/B;0#J_PO^&7P*U*\^&FBZ#X>UMYFFO_`!+-816UU>:]=M;Z>@6%G6*#3PEQ
M>WPN,1?8'PM_X)ZZ7\&_%6DZYX#_`&F/VH+#0H=3M=4\4^"=2^)/_"0:#XX>
MP5EL;/6Y]>T[4=6L["!7:.2WT.^TS[5"SPW+R*Y->9_L#?\`!0'X0?$[X8:#
M\,OB/J5I\&OC!\)_!/AC0_%WA;XB2Q>";*_MM)MH_#]MK'AR\\13V*74,RV-
MK+?:5<&'5M,EOHEFMWB?S%^S=7_:Y_9@T3Q5X+\#W_QW^&'_``E7Q#U9-$\&
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M:I<+H<5C:BW2SEN\R_TI>//'GA/X:>#/%/C_`,<:W8^'?"/@_1K_`%WQ!K6H
MSQP6NGZ=I\1DGE8R,F^5R%AMK:,M/>7<L-I:QRW,\4;_`)_>(+S_`()=?MF1
M7_C7Q/KW[.OQ.N89;3P_J7B75/$MEX5U^3^RH8;^SL9]0GU'POKMW!:P7T0B
MEWSVXA=K$S-'$]M'6;X?ZQ5P[^LX6/LX5>?`8VLZ>%Q4)))2FX2A-RBUIS^U
MII7O3;M(*;233B[-K]Y%7E&W175M=WU.5^#?["'@S1Y+'QO^SQ^W#^TB/AOK
M-UHVH7.D^$_BIX=\>>$_$UMH%_=0K9C7]5TWQ#>P64PBN=(G_LB_LUCABGAB
M>.969?U9CQL7`P,#``Q@=ACC^7TXK^2/]K7PE\/?V2_C'\//"?\`P3C^-_Q,
MN?B#\09[G6?$7P_^'OC6?QQX7LHI;N:W\,(A\-O/;ZPSRR7T;:!J4&JS:5H-
MI/JEQ>6XD6=_ZP/"G]MGPMX;/B8PGQ(=`T<^(3;HL<!UPZ?;G5S#&A94B.H?
M:#&BLRJN%!(&:>2UZ<JF,PL<*\/4PTJ2KNGC*N,PLJE2"DXT*M1I^YJI)0@D
M]+,=:"4824U)23:3BHSCM?FBM=>C;U^\WZ***^@,`K+UG1['7M+U+1=3A6YT
M[5]-OM*O[>15>.>RU"WDM;J%T=61EDAE=65U9&4D,I!-:E-;..!G(.>0#^OX
MU,MGI?576]TFKZ==.G78#^=;_@F_K[?L9_MI?'_]B3QU--I6B>,]:CU+X5:I
MXE6"POO$.H:69W\,M!(&CM;Z7QCX-NC(LEAYD5UJ7AX+:6UJ9;F&+^B@,QVG
M&`PSWR,C.#Z'_P#5VK\C_P#@J-^QWXD^+WA'0?VAO@;IVJVW[2/P4N++5M"O
M_#-[-;>(M;\)Z1<W>LRZ;I=K#%,-2\3Z-J+1:MX<C41W%P8[S1E>:WOQ;-V?
M_!/[_@HGX`_:H\/:3X"\6WY\(?'WPWI=CI6N>&?$5S96MW\0KW2-#M/[>\8>
M%H8+>S@`N]0AU*[O_"J(=8T*.&5IH);.%[L?.9;5CE.)J9+B)*G2]I.OE=24
ME&G5P]:7,\-S2LE5H5)3Y::DY2CRV25D]ZD75BJT-7:U6/5-63FUJ[-:[)7W
MMK;]0**C,L8.TL`W'RD$-STX(SCWQBG;U]?T/^%?277==/QV^^ZMZF`ZHV9E
M4G&<'T.2,@#`&22<\8I1(C$A6R1U`!)&>A(`SCWZ>]?D/_P4,_X*.>'?@?I^
MI?`OX)7-UX__`&B/&MIJ7AFQ3P1?V^H7/PLU[4&@T[2)=3@M;:_DO?%M[>7+
MPZ/X5M%.K0W,,=S?PV\4ENEYR8W'8;`8>6)Q-11IQ5XI-.=62LXTJ45>4YU'
M[J44W9WVU*A"522A!:O=_P`JZM]$EU;=EY['R#^V3XI\0?ML?\%(O@_^R'HM
M_(OPN^#OB33-8\5_V;!%=QS:U96-MXN\:ZG?WL,4JI]BT"VL?#6GP75PMM'<
M76H1>7;7UU(6_HQ@MX[=4CA1(HHHHX(HXU"K'%"H6.-1C`6-`%4`8"\5^8/_
M``3+_8DG_9@^&,GCGXC:=%)^T'\48);_`,?:F=3OM2N]*T6^U`ZQIOA6=[IQ
M"NKV\LJ7?BN:!)([W7%E)N+C[/'/)^HH&/R'\R?ZUYV383$1AB<=C8VQ>95_
MK%2FV[T*'LXQP]"]D[T::C!JR]Y-M<VI=64;J$'>-./*FKVD_M2OM[TE>WW:
M'F/BOX+_``H\=>*_"WCKQE\//"'B?QEX&E\_P9XGUS0K'4=<\+2BX%V)-"U&
MYCDN-.=;H"X#6SQGSAOZUZ;M.W:6)/\`>Y!ZYSD'/ZU_)W^VU^S+^W1XE_X*
M$_\`!0'XH?#SPUKEWIFJ_##]E;5?V)M7\11?M#^.HHOB1X4^&GB>Q\=7_P`!
M_#OPQ^-7PU^"7A/Q!H'CO2/#VH^-[3]HF?3?#VO7UOX>U&&RUC1IM:MM8_I*
M_98G^,<_[./P4/[0GAZ3PM\;8/AQX8L?B=HT_C#3?'MW%XNT[38;#5+[4/%F
MC:/H&D:MJFM26PUK5#IFE6]A9:CJ%UIUI+>06:7US[2IP3E)0C&4[.<HI1E)
MI<J<I*TFTDE=MNVES-MO?H:.C?LW_`7PY\0[OXMZ!\(/AWHWQ/O[S5=1O?'N
MF>%-)L_%5U?ZXK)K-W/K,%NEY)<:HCNM](TNZYWL92Q)S[5@9)ZYQVZ8KY;_
M`&X+'XV:C^QG^UI8?LVOKR?M"WW[-?QNM/@4WA:]L-.\2K\7[CX;>)(OAT?#
MVH:K/:Z;8ZW_`,)<VD?V5>7]S;V=M?>1-<3PQ1M(NM^QWI7C30?V2/V6M!^)
M,6NV_P`1=$_9Q^!^D^/K;Q1=7-[XF@\:Z=\-/#5EXJA\17EY/<W=WKL6NP7\
M>KW5U<W%S/J"W$L\\LK,[*%&E335.G"FI2<Y*G%04IR:<I-023E)I.4GJ^K8
M-M[MOUU/5/'WPP^'WQ4T&[\+?$KP9X8\>>&[X1K=Z)XKT/3M<TZ=8KF*\B5X
M+^"90L=S;P3J$V@20HQSBO&_"W[%7[(W@GQ!I?BOPC^S9\$_#OB71))9M(US
M2?ASX9L]2TV::WEM));2YCT\20NUO/-$2I!VR'!!YKFOV_\`PY^U+XK_`&.O
MCWH?[%GC2#P#^TQ=>![N7X8^('TW1]1U![ZRNK6^UC0/#3>(73P_HWC/Q7X<
MM]7\,>"?%&O+-HOA/Q9J^C^)=5MKBQTN>%_R6'@7]IN/Q#^RSJ/[(GP7_;T^
M"OQI\7?'#]GGQ)^VIXR_:)\=_#G6/A-XA^&_@N^U^V^.T'Q?L?\`A;'CC1-4
M^(WC;P?=WNK^'IOV?O!]AX4OM=\2>$-\WAJ[TB_T3PU$L-AIS]I/#T)U+I^T
ME1IRG=;>^XN6G373H";2LFTNR;7Z_?WZG]$&GZ;8:5:I8Z;9VNGV<6[R;2QM
MH+.UA#L780V]M''#&&=F=MJ`L[,S$DDUG:[X9T'Q/I5]H7B/2-+U[1-3MY[3
M4-)UG3[74M.O+2YB,,]M<6EW'+#)%+&2DBNIW*<`@`5M1AP&W=V)4=<*?NCD
MYR!C<.@;.T[<5^+O_!<3]DCQK^T1^Q;X_P#$GP#\%_$GQ/\`M5>"[OX36GPJ
MNOA;\3O'?@+Q98>$KKX]?#._^,$>FP>&O''A'1=5DE^%=OXT%VNI07^KS:8;
MVTT,-J<]I"VKA%QY7%..W+96MV2V7R%KO=W5M;N^FVNY]R/_`,$^_P!B.2X2
MY;]E;X%ETMY;;R_^%<^'1:M'/)%*[R6@LQ;O.&A`BN7C,\4;RQ)((Y9%;Z/\
M#_#SP-\,_#VG>$OAYX2\.^"O"VDQ"'3?#_AC2++1M*LH@\DGEP6=A#!"J^9-
M*XRI(>5R#\QKA/@5^SS\*/V;?#&I^"_@[X;O_"_AK5O$%SXFOK'4/&7CCQK/
M/K-W86&FS78U/Q[XD\4:M;QM9:780BPM;Z#3XWB>XCM%N)[B67VTG`SD#&"2
M>@`/S?IG!Z`]>*RAA<-3FZE/#T:=25TZD*4(3:=FTYQBI.]E?76R[#<I/>4G
MZMO\V(RJZLC`,K*596&596!!!'<$$@CN.*^4+O\`81_8RU"XFN]0_9=^!E[<
MW,\]U<3W7PV\,SRRW-U*\]S.[S6+L9)YG>65NKNS,Q).:_`C_@D!X5^+W@W]
MH;P7X?\`C=^R?\??"OB_3?#'Q*@U?XY_$/P?^U%-]N\7RWE[<SWGB/XC?$+]
MIGQC\*-7L-9M);VRTHZ-\(=,MYS-H\'ARVT2PMPJ_P!4XZ#/H*JI0H5G%UJ-
M*JX7<'4IQJ<C=DW#G3Y;I*_+:]E>]@4I*]I-7WLVKVVO;>Q\X^!_V/\`]EGX
M9^*--\;?#O\`9\^#_@GQAHPN_P"R/$_AGP#X=TC7-+-]:S6-VUCJ5G8Q7-LU
MQ:7$UO*T4BEX99(VRK$'Z,1-@QN)'N`/Y?\`ZSW)/-?C?^V#X?\`VI;C]LG0
M+CXA>'_CO\4?^";?B[X":GX$\0>`_P!EG6=&T/Q!X2^*&H>*=/E\8^,/VAM/
M76O#?Q<\6^!+WP4L5AX+?X$Z[/XAT**/QDNH>&-0U.\T&>;]*OV>#HD?P=\%
M:9X9^&?Q#^$'AGP[8W7A7PWX`^*DD4_C;2-`\+ZC>:#H]UJ=POB_QW=7-KK>
MGZ?!KFCW&K^)KW7YM'U&P?Q!!INLF^TRT=.C2I1<:5*G2B[WC3A&";>C;44M
M797>XFV]6[ONS=\??!GX4_%/4?"FK?$?X>>#_&^I^!=0?5O!M_XGT&PUB[\+
MZH]QI]V^H:'/>PROIUVUUI6F7#3VQ20S6%H^[="F/2P,8YSU_4@_TKY[_:WT
MOQ=KG[*O[3.A_#Z+7+CQ]K7[/?QITKP/;^&+FXL_$MQXOU#X<^([/PU#X>O+
M2:WNK37)=:GL8](N;:X@N(-0>WD@FBE577\5OCO\&_\`@KYXBT;_`()8Z'XR
M\3?"7XAZ'\-OVZ_V-O&'QWU7]G32/BU\*_B3=?#KP'X<\4O\2?%7Q<;Q%\3)
M_!E[\/);5)I_'_@BVTZXMM:\0WFB66CZ5.4M]/=QITXRE.,(QE/E<Y1BE*?+
M'ECSR5G/ECI'F;LK);(+OOMMY']%I&1CI7E_Q/\`@E\(_C58:;I?Q<^&_@SX
MD:;HUS/>Z58^,]`T_7[73KVY@^RW-U9P:A%-%;SSVW[B22-5=H\J6(XKU!6#
M`,I!!Z$=Z6G.$)IQG",XO>,XJ2?JFFF!7M;6&RMX;2VCC@M;:&*WMK>)%CAM
MX($$4,,2+PD<<2I&BCA50``"I)(ED1D;E6R"",@ALY!'&002",X(/2I*_,/_
M`(*L_#_]H#XD?!C]GW0_V<;#QUJ'C#3OVZ_V.?%7BV+P#KMSX>U"'X1^%?C'
MHNN?%6[UR_M]4TA)/"5KX-L]2E\1:?=W4EIJ5DILGM+R6:&WD?*NW;JULK+;
MI;2VSZ@?;WPR^`/P4^"]WKE]\)?A9X$^'%WXF%HOB*Y\&^&M-T";6UL)+N:R
M74I-/AA:[6TEO[V2W$VX1/=3LF/,?=ZYM/=L].P[9Z>G7J*4$,,@Y'^!P?R/
M!K\J?^"E_P`$_CI\=?&?["/A?X+^-_B_\+K;3?VE?%.O^//BK\(M1FMY_AM8
MZ=^SS\8)/`GBWQEHLMU%H/C'P?8?%8>!QJ7@WQ7:ZAX<\2F2/1]0MDCO/M$,
MQIPA'EA",(J[48144FW=M**5FWJVM^H/7=M[=7TV_+8^W?B1^RW^SG\8M:MO
M$?Q6^"'PN^(?B"SLO[.MM9\7>"M#UO48;$3S7*VJ75]:RR^4)[F>4`L2))I&
M!&XU<^'7[-?[/WPC-^?AC\%OA?X#;5)[2ZU%_"O@C0-'>\N+!2ME/-):62.T
MMH&/V>3<&B)RN"!7Y;_L2:)^W[)_P44^-_B']L'1=:M_#^@_L6?`3X96'BKP
M?JNIS_LV>/\`XH>'O'WC;4?%WCOX2Z/>36SZ)JOB_2]1TW6_%6A:SHXU[PGJ
M%Q/X777_`!!H>G:5?/\`MG(&*D+U^N/QS@]#@CU(P>,UE]4PO-S_`%>ASWYN
M?V4.;FTUYN6]]-[W^]E<TMN:5NUW_F4KW2K#4;62QU"TM;^RFV^?9WMM#=VE
MP$=9$$]O<)+%,$D1)$$BMMD19!\ZJ5^>/'?[&O[*?Q.UBX\0^/\`]GOX2>*?
M$%U;V=I<:[J?@C0WUB2UT\_Z';?VE%:1W:00)^Y6-)55H&>%PT<CJ?R\^(_A
M'XRZK^U;\?O#O[<_P;_:<^/W[-'B/XA>#O$W['VJ_LZ:Q/;?!SX=^%[?P%>6
MTWAWXL>'OA_\1/`'Q6M?BB?'>D:OIZZYJ.E^+?`-W;^,_"][J&K:#;&_ET7]
ML/!/B"Z\5^%-`\2WOA?Q/X)N]<TNSU*X\(>-(=(M_%GAN6Z@25]'\0P:!K'B
M'1(=6LBWDWB:7KFJV0E4^1?3IAS53#8>LK5J%&JEHE4I0J)+:UI1?302;6S:
M]&U^1P_PV_9\^"'P;2\C^$WPF^'GPX&H7HU&]/@WPCHF@M<WJVOV%;J1["TA
MD$XLB;7S$=&,#-'G:S`^PJH554=%``_`8KSCXL^/;WX9^!]3\8Z=\._B+\5K
MW3[O1;2W\"?"G3?#^K>.=9?6=:T_1FFTJR\4^)?"&@&UT>._?6M;N-2\1:=%
M9Z'IVI741N+B&*UF[^SG-S:6UPT%Q:M/;PS-;78C%U;-+&KM;W(AEGA%Q"S&
M*81331"16$<LB`.;ITJ5**A2ITZ4%>T:<(PCJ[O2*2WN]NK[L3;;NW=]WJ_O
M+-%%%6`4444`,=<@?,5.>".N3^H_`BOR2_;7_P""7'A#]H?Q-<?&7X0>*G^#
MGQXM8+>:+4=.MHK/PGXGU.P>XFM=1UA=&AM=7T;Q)-)/MN?%FG375Y-%!:Q7
M-I((Q<Q_KA1@>GO^/K7'C<#A\?1=#%4XU*3DI)?#*,XM.-2,U[T9Q:3@XM6:
M3U+A.5.7-%V?7LUV:ZKR9_.3H7[3/_!53]BS1]+\(?&KX!2?'[PAX?TV,67C
M"TFU;Q1K3V.Y8;2SO?B#X476;G5+G3U$*2G5O"USK!$H:]U*^),D>Q_P^:_:
M5'_-A7BC_P`#/B?_`/.EK^A[`'08HKS(Y1F%!*GA<]QE.A'2G3KT,/BIPCHE
M%5:BC)Q26B:=NYI[6F]94(MWOI*45NF]%>VJ^X_FY\5_&;_@K'^W'I5UX/\`
MAQ\&[G]G;X<Z['#?W/B0S:EX'U"YTV&YMY%TN;X@:_-9:V6N([RPGDT_0?#N
MC7^H6UM>PW%W]EEN-/?[[_85_P"":7@#]E4GX@^-M2@^)_QWURP1=<\37]G:
MW/A[PO>2W2ZA<CP3#J%F^J0ZB;L>7?>*+J[34M5@508+.-I4F_4L@'J`?K_G
MV%&!Z=.GM5X?(Z-/$QQF*Q.)S#%QNXUL3.*A2=DKT,-3C'#TI<MX\RIM\K:3
MU=YE5DX\L8Q@KWT6K[WEN_O5^HU%V`C).26Y]3R?S.3Z<\<4ZBBO<6B1D1>4
M.<,=K9)7MSP>^<$=0<_[.WC#U7:H4$D`8R>OZ4ZB@`IB)M+'))8Y/8?EZGJ2
M>2:?10`4PH&8,2?E((P2,8&.QY^AXZ\<T^B@`IK+NP02"N<$9XR,'C."<=,@
MX/(%.HH`11M`'7`QG@?H,"E(R"#@@C&",C\1W'M110!'Y>>KN?49(!'H`",8
M/((.?4M4@X`HHH`1AD$`X/'(ZC!S_GMZ@]*1%V+C);J23C))Y).,=3D_YS3J
M*`&.F_:<D%3D=Q^7J,9![&E9=PQG@]>,_I_C^5.HH`:BA%"@D@#`+$DGZD]:
M=110`4C#(QG'Z\=QCW&1^O:EHH`:JA%"@DXSR>O)R?U-(R;L?,5]<=QZ$'@]
M^H/7Z4^B@!B)LS@G!['IGC)'IGDX''/`&*?110!'Y8W,X)#$`9XX`[#V/4@]
M2!SCBECC$8(!)R<\]O8=3@=LDX'&>!3Z*`(WCW[?F9=N?NGJ",$,#D$=^F<@
M8."P9ZJ%`4=`,`<\`=N23CTYX'%+10`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
4`!1110`4444`%%%%`!1110!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
